The Psychopharmacologic Drugs Advisory Committee will meet on Friday 17June 2022 to discuss supplemental new drug applications (sNDA) ( 210793-s008) and (207318-s011), efficacy supplement resubmission for NUPLAZID (pimavanserin) tablets, submitted by Acadia Pharmaceuticals Inc., for the proposed treatment of hallucinations and delusions associated with Alzheimer's disease psychosis.